CINXE.COM

Sciinov Group

<!DOCTYPE html> <html lang="en"> <meta http-equiv="content-type" content="text/html;charset=utf-8" /> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta http-equiv="X-UA-Compatible" content="ie=edge"> <title>Sciinov Group</title> <link rel="apple-touch-icon" sizes="180x180" href="assets/images/favicon/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="assets/images/favicon/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="assets/images/favicon/favicon-16x16.png"> <link rel="manifest" href="assets/images/favicon/site.webmanifest"> <!-- For Window Tab Color --> <!-- Chrome, Firefox OS and Opera --> <meta name="theme-color" content="#cd2828"> <!-- Windows Phone --> <meta name="msapplication-navbutton-color" content="#cd2828"> <!-- iOS Safari --> <meta name="apple-mobile-web-app-status-bar-style" content="#cd2828"> <link href="https://fonts.googleapis.com/css?family=Arimo:400,400i,700,700i%7CMerriweather:400i&amp;display=swap" rel="stylesheet"> <!-- plugins styles --> <link rel="stylesheet" href="assets/css/animate.css"> <link rel="stylesheet" href="assets/css/bootstrap.min.css"> <link rel="stylesheet" href="assets/css/bootstrap-datepicker.min.css"> <link rel="stylesheet" href="assets/css/bootstrap-select.min.css"> <link rel="stylesheet" href="assets/css/hover-min.css"> <link rel="stylesheet" href="assets/css/magnific-popup.css"> <link rel="stylesheet" href="assets/css/owl.carousel.min.css"> <link rel="stylesheet" href="assets/css/owl.theme.default.min.css"> <link rel="stylesheet" href="assets/css/nouislider.css"> <link rel="stylesheet" href="assets/css/nouislider.pips.css"> <link rel="stylesheet" href="assets/css/jquery.bootstrap-touchspin.min.css"> <link rel="stylesheet" href="assets/css/jquery.mCustomScrollbar.min.css"> <!-- icon styles --> <link rel="stylesheet" type="text/css" href="assets/css/politaro-icons.css"> <link rel="stylesheet" type="text/css" href="assets/css/simple-line-icons.css"> <link rel="stylesheet" type="text/css" href="assets/css/fontawesome-all.min.css"> <!-- main styles --> <link rel="stylesheet" href="assets/css/style.css"> <link rel="stylesheet" href="assets/css/responsive.css"> </head> <body> <div class="preloader" style="background-image: url(assets/images/resources/preloader.svg);"></div><!-- /.preloader --> <div class="page-wrapper"> <div class="site-header__header-one-wrapper"> <header class="site-header site-header__header-one "> <nav class="navbar navbar-expand-lg navbar-light header-navigation stricky"> <div class="container clearfix"> <!-- Brand and toggle get grouped for better mobile display --> <div class="logo-box"> <a class="navbar-brand" href="index.php"> <img src="https://sciinovgroup.com/uploads/images/11640844025.png" class="main-logo" alt="Awesome Image" /> </a> <button class="menu-toggler side-menu__toggler"> <span class="fa fa-bars"></span> </button> </div><!-- /.logo-box --> <!-- Collect the nav links, forms, and other content for toggling --> <div class="main-navigation main-nav__main-navigation"> <ul class=" navigation-box " id="mainNav"> <li class=" dropdown"><a href="index.php">HOME</a></li><!--current--> <li><a href="#about" class="">ABOUT US</a></li> <li><a href="#events">EVENTS </a></li> <li><a href="#contact">REQUEST INFO</a></li> </ul> </div><!-- /.navbar-collapse --> <div class="right-side-box"> <a href="request-info.php" class="thm-btn header-donation__btn">Get in Touch</a> </div><!-- /.right-side-box --> </div> <!-- /.container --> </nav> </header><!-- /.site-header --> </div><!-- /.site-header__header-one-wrapper --> <section class="inner-banner" style="background-image: url(assets/images/backgrounds/inner-banner-about-bg.jpg);"> <div class="container text-center"> <h2 class="inner-banner__title">News and Announcements</h2><!-- /.inner-banner__title --> <ul class="list-unstyled thm-breadcrumb"> <li><a href="index.php">Home</a></li> <li>News and Announcements</li> </ul><!-- /.thm-breadcrumb --> </div><!-- /.container --> </section><!-- /.inner-banner --> <section class="blog-one"> <div class="container"> <div class="row"> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=1">Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=1"><i class="far fa-calendar"></i>01/06/2022</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=12">RegenxBIO Announces FDA Clearance Of IND For Clinical Trial Of RGX-202, A Novel Gene Therapy Candidate For Duchenne Muscular Dystrophy</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=12"><i class="far fa-calendar"></i>01/06/2022</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=13">Coherus Announces U.S. FDA Approval of YUSIMRY (adalimumab-aqvh)</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=13"><i class="far fa-calendar"></i>12/20/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=14">Novavax Announces Submission of New Drug Application in Japan for Approval of COVID-19 Vaccine</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=14"><i class="far fa-calendar"></i>12/17/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=15">Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Medulloblastoma</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=15"><i class="far fa-calendar"></i>12/17/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=16">Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO (budesonide) to Reduce Proteinuria in IgA Nephropathy</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=16"><i class="far fa-calendar"></i>12/16/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=17">Merck Announces Positive Phase III Results for Arpraziquantel as Part of its Schistosomiasis Elimination Program</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=17"><i class="far fa-calendar"></i>11/16/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=18">Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=18"><i class="far fa-calendar"></i>11/15/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=19">BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA (Zanubrutinib) in Waldenstroms Macroglobulinaemia</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=19"><i class="far fa-calendar"></i>08/18/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=20">Novartis secures new approval in China for Cosentyx (secukinumab) in pediatric psoriasis</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=20"><i class="far fa-calendar"></i>08/17/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=21">Positive CHMP opinion for Otsuka's child-friendly 25 mg film-coated tablet formulation Deltyba (Delamanid) for use in pediatric patients weighing 10 kg or more with pulmonary multi-drug-resistant tuberculosis in the EU</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=21"><i class="far fa-calendar"></i>07/27/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=22">Allegro Ophthalmics Announces Positive Results of Vehicle-controlled Ex-U.S. Phase 2 Trial of ALG-1007 for the Treatment of Dry Eye Disease</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=22"><i class="far fa-calendar"></i>07/27/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=23">Japan becomes the first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=23"><i class="far fa-calendar"></i>07/20/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=24">VALNEVA AND PFIZER COMPLETE RECRUITMENT FOR PHASE II TRIAL OF LYME DISEASE VACCINE CANDIDATE</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=24"><i class="far fa-calendar"></i>07/19/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=25">Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=25"><i class="far fa-calendar"></i>07/12/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=26">Interim Results from Phase II Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=26"><i class="far fa-calendar"></i>07/12/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=27">Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=27"><i class="far fa-calendar"></i>07/08/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=28">DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU Initiated in Patients with HER2 Positive Advanced Gastric Cancer</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=28"><i class="far fa-calendar"></i>07/08/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=29">FoundationOne CDx Receives FDA-Approval as a Companion Diagnostic for ALUNBRIG (brigatinib) to Identify Patients with ALK positive Metastatic Non-Small Cell Lung Cancer</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=29"><i class="far fa-calendar"></i>07/01/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=30">Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=30"><i class="far fa-calendar"></i>06/29/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=31">Enspryng (satralizumab) from Chugai, approved by the European Commission as the first subcutaneous home treatment for Neuromyelitis Optica Spectrum Disorders (NMOSD)</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=31"><i class="far fa-calendar"></i>06/29/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=32">DARZALEX (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=32"><i class="far fa-calendar"></i>06/22/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=33">BeiGene Announces China NMPA Approval of BRUKINSA (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=33"><i class="far fa-calendar"></i>06/21/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=34">Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa (copanlisib) and rituximab in the U.S. and EU</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=34"><i class="far fa-calendar"></i>06/21/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=35">ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=35"><i class="far fa-calendar"></i>06/18/2021</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=36">Sciinov Healthcare to announce its new Edition 2023 Conference on LONGEVITY</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=36"><i class="far fa-calendar"></i>September 19th, 2022</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=37">DENTAL MEET 2023 - Dubai attracts world-renowned Speakers and large international audience</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=37"><i class="far fa-calendar"></i>09/28/2022</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> <div class="col-lg-6 col-md-6 col-sm-6"> <div class="blog-one__single"> <h3><a href="news-details.php?id=38">The “Spectacular Progress” In Research Into Slowing Down Aging, Analyzed In Cell By Maria A. Blasco And Other Leading Researchers In The Field</a></h3> <ul class="list-unstyled blog-one__meta"> <li> <a href="news-details.php?id=38"><i class="far fa-calendar"></i>27 Jan, 2023</a> </li> </ul><!-- /.list-unstyled --> </div><!-- /.blog-one__single --> </div><!-- /.col-lg-4 col-md-6 col-sm-12 --> </div><!-- /.row --> </div><!-- /.container --> </section><!-- /.blog-one --> </div><!-- /.page-wrapper --> <div class="side-menu__block"> <a href="#" class="side-menu__toggler side-menu__close-btn"> <i class="fa fa-times"></i> </a> <div class="side-menu__block-overlay custom-cursor__overlay"> <div class="cursor"></div> <div class="cursor-follower"></div> </div><!-- /.side-menu__block-overlay --> <div class="side-menu__block-inner "> <a href="index.php" class="side-menu__logo"><img src="https://sciinovgroup.com/uploads/images/11640844025.png" alt="Awesome Image" /></a> <nav class="mobile-nav__container"> <!-- content is loading via js --> </nav> <p class="side-menu__block__copy">(c) 2021 <a href="#" class="text-uppercase">Sciinov Group</a> - All rights reserved.</p> <div class="side-menu__social"> <!-- only fontawesome's brand icon --> <a href="#"><i class="fa fa-facebook-f"></i></a> <a href="#"><i class="fa fa-linkedin-in"></i></a> <a href="#"><i class="fa fa-twitter"></i></a> <a href="#"><i class="fa fa-instagram"></i></a> <a href="#"><i class="fa fa-pinterest-p"></i></a> </div> </div><!-- /.side-menu__block-inner --> </div><!-- /.side-menu__block --> <a href="#" data-target="html" class="scroll-to-target scroll-to-top"><i class="fa fa-angle-up"></i></a> <script src="assets/js/jquery.min.js"></script> <script src="assets/js/bootstrap.bundle.min.js"></script> <script src="assets/js/bootstrap-datepicker.min.js"></script> <script src="assets/js/bootstrap-select.min.js"></script> <script> // Cache selectors var lastId, topMenu = $("#mainNav"), topMenuHeight = topMenu.outerHeight()+1, // All list items menuItems = topMenu.find("a"), // Anchors corresponding to menu items scrollItems = menuItems.map(function(){ var item = $($(this).attr("href")); if (item.length) { return item; } }); // Bind click handler to menu items // so we can get a fancy scroll animation menuItems.click(function(e){ var href = $(this).attr("href"), offsetTop = href === "#" ? 0 : $(href).offset().top-topMenuHeight+1; $('html, body').stop().animate({ scrollTop: offsetTop // scrollTop: $($(this).attr('href')).offset().top - 150 }, 850); e.preventDefault(); }); // Bind to scroll $(window).scroll(function(){ // Get container scroll position var fromTop = $(this).scrollTop()+topMenuHeight; // Get id of current scroll item var cur = scrollItems.map(function(){ if ($(this).offset().top < fromTop) return this; }); // Get the id of the current element cur = cur[cur.length-1]; var id = cur && cur.length ? cur[0].id : ""; if (lastId !== id) { lastId = id; // Set/remove active class menuItems .parent().removeClass("active") .end().filter("[href=#"+id+"]").parent().addClass("active"); } }); </script> <script src="assets/js/isotope.js"></script> <script src="assets/js/jquery.counterup.min.js"></script> <script src="assets/js/jquery.magnific-popup.min.js"></script> <script src="assets/js/jquery.validate.min.js"></script> <script src="assets/js/owl.carousel.min.js"></script> <script src="assets/js/TweenMax.min.js"></script> <script src="assets/js/jquery.enllax.min.js"></script> <script src="assets/js/waypoints.min.js"></script> <script src="assets/js/wow.min.js"></script> <script src="assets/js/jquery.mCustomScrollbar.concat.min.js"></script> <script src="assets/js/circle-progress.min.js"></script> <script src="assets/js/countdown.min.js"></script> <script src="assets/js/jquery.ajaxchimp.min.js"></script> <script src="assets/js/nouislider.js"></script> <script src="assets/js/jquery.bootstrap-touchspin.min.js"></script> <script src="assets/js/theme.js"></script> <script> $(document).ready(function(){ $('.myslider').owlCarousel({ items:1, nav: true, dots: true, dotsData: true, }); }); </script> </body> </html>

Pages: 1 2 3 4 5 6 7 8 9 10